Ballentine Partners LLC Purchases New Stake in HealthEquity, Inc. (NASDAQ:HQY)

Ballentine Partners LLC acquired a new position in HealthEquity, Inc. (NASDAQ:HQY - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,377 shares of the company's stock, valued at approximately $228,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. UMB Bank n.a. boosted its stake in shares of HealthEquity by 65.6% in the fourth quarter. UMB Bank n.a. now owns 414 shares of the company's stock valued at $40,000 after purchasing an additional 164 shares during the period. HB Wealth Management LLC purchased a new position in HealthEquity in the 4th quarter valued at approximately $261,000. Avanza Fonder AB acquired a new position in shares of HealthEquity in the fourth quarter worth $381,000. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of HealthEquity during the fourth quarter worth $215,000. Finally, Radnor Capital Management LLC raised its stake in shares of HealthEquity by 8.3% in the fourth quarter. Radnor Capital Management LLC now owns 5,690 shares of the company's stock valued at $546,000 after acquiring an additional 436 shares in the last quarter. Institutional investors and hedge funds own 99.55% of the company's stock.

Insider Buying and Selling at HealthEquity

In other news, Director Robert W. Selander sold 8,250 shares of the business's stock in a transaction on Monday, December 9th. The stock was sold at an average price of $101.56, for a total value of $837,870.00. Following the completion of the transaction, the director now directly owns 66,469 shares of the company's stock, valued at $6,750,591.64. The trade was a 11.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Stuart B. Parker sold 25,000 shares of the stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $96.72, for a total value of $2,418,000.00. Following the sale, the director now directly owns 19,061 shares in the company, valued at approximately $1,843,579.92. The trade was a 56.74 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 34,289 shares of company stock worth $3,355,718. 2.20% of the stock is owned by corporate insiders.

HealthEquity Stock Performance

Shares of HQY stock traded up $2.17 during trading hours on Friday, reaching $106.88. 654,597 shares of the company's stock were exchanged, compared to its average volume of 607,718. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20. The company's 50 day moving average is $99.60 and its two-hundred day moving average is $87.45. The company has a market cap of $9.26 billion, a P/E ratio of 98.06, a price-to-earnings-growth ratio of 1.86 and a beta of 0.54. HealthEquity, Inc. has a 1 year low of $65.01 and a 1 year high of $107.87.

HealthEquity (NASDAQ:HQY - Get Free Report) last issued its earnings results on Monday, December 9th. The company reported $0.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.71 by ($0.12). HealthEquity had a net margin of 8.41% and a return on equity of 9.70%. During the same quarter in the previous year, the firm earned $0.40 earnings per share. Equities research analysts anticipate that HealthEquity, Inc. will post 2.32 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on HQY shares. BTIG Research upped their price target on HealthEquity from $110.00 to $130.00 and gave the stock a "buy" rating in a report on Thursday, November 14th. JMP Securities upped their target price on shares of HealthEquity from $105.00 to $107.00 and gave the stock a "market outperform" rating in a research note on Tuesday, December 10th. Mizuho assumed coverage on shares of HealthEquity in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $126.00 price target for the company. Barrington Research increased their price objective on shares of HealthEquity from $105.00 to $120.00 and gave the company an "outperform" rating in a research report on Monday, December 2nd. Finally, The Goldman Sachs Group started coverage on shares of HealthEquity in a research report on Friday, November 15th. They set a "neutral" rating and a $108.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $110.71.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.